Double-Drug attack tested for stubborn blood disorder
NCT ID NCT07234019
Summary
This study is testing whether adding a second drug (anti-CD38) to a standard treatment (rituximab) works better for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low after steroid therapy. Researchers will compare the safety and effectiveness of the two-drug combination against rituximab alone in 160 participants. The goal is to see if this approach provides a stronger, longer-lasting response for this difficult-to-treat condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Science and Blood Disease Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.